We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nine mid-sized drugmakers agreed to lower prescription drug prices under Trump's MFN pricing proposal.
The companies committed at least $19.6 billion collectively to near-term U.S. manufacturing.
The nine deals lift MFN coverage to 26 drugmakers, spanning 89% of the branded drug market.
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma (ALPMY - Free Report) , BeOne Medicines (ONC - Free Report) , BridgeBio Pharma (BBIO - Free Report) , CSL (CSLLY - Free Report) , Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals (TEVA - Free Report) and UCB (UCBJY - Free Report) .
Drug Pricing Deals Leave Some Details Unclear
Under the agreements, these companies agreed to reduce the prices of their prescription drugs to match those in comparable developed countries, as part of President Trump’s Most-Favored-Nation (“MFN”) pricing proposal. However, the announcement does not provide details on the drugs that will be covered or specify the exact size of the price reductions for individual medicines.
In return, each drugmaker will receive a reprieve from import tariffs on pharmaceutical ingredients, contingent upon expanding its domestic manufacturing operations. According to a White House disclosure, these nine companies are committed to investing at least $19.6 billion collectively in U.S. manufacturing in the near term.
New Pharma Deals Also Include API Supply Commitments
Some of the participating drugmakers have also agreed to contribute active pharmaceutical ingredients (API) for key products to a government stockpile reserve called the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The reserve is intended to reduce reliance on foreign suppliers and help ensure adequate supplies of critical medicines during emergencies.
In this connection, Astellas has agreed to contribute 25 kg of tacrolimus, which is used to help prevent organ rejection in people who have had organ transplants. In contrast, Teva will supply 45 metric tons of metronidazole, used to treat certain bacterial and parasitic infections, as well as 4.8 tons of amlodipine, a drug used to lower blood pressure.
Meanwhile, UCB has agreed to provide 163 tons of levetiracetam, which is used to control and prevent seizures, while Sun Pharma plans to contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline, antibiotics used to treat bacterial infections.
Trump’s MFN Push Now Covers 26 Drugmakers
The latest agreements build on the administration’s earlier push to secure MFN pricing from the industry’s largest pharmaceutical companies. Pfizer became the first drugmaker to sign such an agreement with the Trump administration in September 2025. This was followed by 16 other major pharmaceutical manufacturers, with Regeneron being the last to sign in April 2026.
With the addition of the nine mid-sized companies, the total number of drugmakers with MFN agreements has risen to 26. The White House said the agreements now cover 89% of the branded drug market.
Notably, the latest group is more geographically diverse than the first 17 companies, which were predominantly based in the United States and Europe. The new cohort includes Sun Pharma from India, Teva Pharmaceuticals from Israel, Astellas and Kyowa Kirin from Japan and CSL from Australia, broadening the reach of the administration’s MFN pricing campaign beyond its earlier focus.
Our Take: MFN Push Enters a New Phase
The expansion to nine mid-sized drugmakers suggests that the administration’s MFN strategy is moving beyond its initial focus on Big Pharma and becoming a broader industry-wide pricing push. With 26 drugmakers now covered and the administration continuing to pursue additional agreements, the pressure on other manufacturers to strike similar deals could intensify in the coming months.
If this momentum continues, the policy could eventually move beyond voluntary agreements and toward a more permanent framework. The Trump administration has also called on Congress to codify its MFN agreements into law through the Great Healthcare Plan, potentially giving the policy a longer-term footing if enacted.
The timing of the latest agreements is notable, as the administration heads toward the November 2026 midterm elections. Continued announcements around lower drug prices could help reinforce the administration’s message on healthcare affordability, particularly as TrumpRx.gov has already become a key component of its drug-pricing strategy. The White House said the platform has generated more than $700 million in savings since its February launch, with GLP-1 drugs among the most prominent examples of discounted medicines.
View the Zacks #1 Rank List
Image: Bigstock
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Key Takeaways
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma (ALPMY - Free Report) , BeOne Medicines (ONC - Free Report) , BridgeBio Pharma (BBIO - Free Report) , CSL (CSLLY - Free Report) , Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals (TEVA - Free Report) and UCB (UCBJY - Free Report) .
Drug Pricing Deals Leave Some Details Unclear
Under the agreements, these companies agreed to reduce the prices of their prescription drugs to match those in comparable developed countries, as part of President Trump’s Most-Favored-Nation (“MFN”) pricing proposal. However, the announcement does not provide details on the drugs that will be covered or specify the exact size of the price reductions for individual medicines.
In return, each drugmaker will receive a reprieve from import tariffs on pharmaceutical ingredients, contingent upon expanding its domestic manufacturing operations. According to a White House disclosure, these nine companies are committed to investing at least $19.6 billion collectively in U.S. manufacturing in the near term.
New Pharma Deals Also Include API Supply Commitments
Some of the participating drugmakers have also agreed to contribute active pharmaceutical ingredients (API) for key products to a government stockpile reserve called the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The reserve is intended to reduce reliance on foreign suppliers and help ensure adequate supplies of critical medicines during emergencies.
In this connection, Astellas has agreed to contribute 25 kg of tacrolimus, which is used to help prevent organ rejection in people who have had organ transplants. In contrast, Teva will supply 45 metric tons of metronidazole, used to treat certain bacterial and parasitic infections, as well as 4.8 tons of amlodipine, a drug used to lower blood pressure.
Meanwhile, UCB has agreed to provide 163 tons of levetiracetam, which is used to control and prevent seizures, while Sun Pharma plans to contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline, antibiotics used to treat bacterial infections.
Trump’s MFN Push Now Covers 26 Drugmakers
The latest agreements build on the administration’s earlier push to secure MFN pricing from the industry’s largest pharmaceutical companies. Pfizer became the first drugmaker to sign such an agreement with the Trump administration in September 2025. This was followed by 16 other major pharmaceutical manufacturers, with Regeneron being the last to sign in April 2026.
With the addition of the nine mid-sized companies, the total number of drugmakers with MFN agreements has risen to 26. The White House said the agreements now cover 89% of the branded drug market.
Notably, the latest group is more geographically diverse than the first 17 companies, which were predominantly based in the United States and Europe. The new cohort includes Sun Pharma from India, Teva Pharmaceuticals from Israel, Astellas and Kyowa Kirin from Japan and CSL from Australia, broadening the reach of the administration’s MFN pricing campaign beyond its earlier focus.
Our Take: MFN Push Enters a New Phase
The expansion to nine mid-sized drugmakers suggests that the administration’s MFN strategy is moving beyond its initial focus on Big Pharma and becoming a broader industry-wide pricing push. With 26 drugmakers now covered and the administration continuing to pursue additional agreements, the pressure on other manufacturers to strike similar deals could intensify in the coming months.
If this momentum continues, the policy could eventually move beyond voluntary agreements and toward a more permanent framework. The Trump administration has also called on Congress to codify its MFN agreements into law through the Great Healthcare Plan, potentially giving the policy a longer-term footing if enacted.
The timing of the latest agreements is notable, as the administration heads toward the November 2026 midterm elections. Continued announcements around lower drug prices could help reinforce the administration’s message on healthcare affordability, particularly as TrumpRx.gov has already become a key component of its drug-pricing strategy. The White House said the platform has generated more than $700 million in savings since its February launch, with GLP-1 drugs among the most prominent examples of discounted medicines.